Synthesis and characterization of pyrrolidine derivatives as potent agonists of the human melanocortin-4 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 23, 2007, Pages 6546-6552

  Jiang, Wanlong ^a   Tran, Joe A ^a   Tucci, Fabio C ^a   Fleck, Beth A ^a   Hoare, Sam R ^a   Markison, Stacy ^a   Wen, Jenny ^a   Chen, Caroline W ^a   Marinkovic, Dragan ^a   Arellano, Melissa ^a   Foster, Alan C ^a   Chen, Chen ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Agonist; Antagonist; Efficacy; Melanocortin 4 receptor; Potency; Pyrrolidine; Synthesis

Indexed keywords

4 PHENYLPYRROLIDINE 3 CARBOXAMIDE DERIVATIVE; MELANOCORTIN 4 RECEPTOR; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEBENZYLATION; DIASTEREOISOMER; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOMER; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OBESITY; RAT; STEREOCHEMISTRY; X RAY CRYSTALLOGRAPHY;

ANIMALS; BIOLOGICAL AVAILABILITY; HUMANS; INJECTIONS, INTRAVENOUS; PROTEIN BINDING; PYRROLIDINES; RATS; RATS, ZUCKER; RECEPTOR, MELANOCORTIN, TYPE 4;

RATTUS;

EID: 35649017162     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.079     Document Type: Article

References (14)

1. Cone R.D. Nat. Neurosci 8 (2005) 571
2. Yang Y.K. Obes. Rev. 4 (2003) 239
3. For a recent review, see:. Chen C. Prog. Med. Chem. 45 (2007) 111
4. Ujjainwalla, F. 230th ACS National Meeting, Washington, DC, USA. 2005, MEDI 275.
5. Jiang W., Tucci F.C., Chen C.W., Arellano M., Tran J.A., White N.S., Marinkovic D., Pontillo J., Fleck B.A., Wen J., Saunders J., Madan A., Foster A.C., and Chen C. Bioorg. Med. Chem. Lett. 16 (2006) 4674
6. Jiang W., Chen C., Marinkovic D., Tran J.A., Chen C.W., Arellano L.M., White N.S., and Tucci F.C. J. Org. Chem. 70 (2005) 8924
7. Wolfe J.P., and Buchwald S.L. J. Org. Chem. 65 (2000) 1144
8. For experimental detail, see: WO 2005/040109.
9. Karlsson S., Han F., Hogberg H.-E., and Caldirola P. Tetrahedron: Asymmetry 10 (1999) 2605
10. Karlsson S., and Hogberg H.-E. Tetrahedron: Asymmetry 12 (2001) 1975
11. CCDC 661517 (for 15-2) and CCDC 661518 (for 16-1) contain the supplementary crystallographic data for this paper. These data can be obtained via the CDCC website (www.ccdc.cam.ac.uk), or by contacting The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK.
12. Nickolls S.A., Cismowski M.I., Wang X., Wolff M., Conlon P.J., and Maki R.A. J. Pharmacol. Exp. Ther. 304 (2003) 1217
13. 50) in the absence of antagonist.
14. Male CD rats (Charles River) were fed a high fat diet from weaning until 12 weeks of age. Food was removed 24 h prior to testing. On the test day rats were injected ip with vehicle (sterile water), 5 mg/kg fenfluramine (Sigma), or 3, 10, or 30 mg/kg of 20f-1. Rats were then placed into individual test cages with water available. Fifteen minutes after dosing, pre-measured test diet was presented to the rats and food intake was measured 1, 2, 4, 6, and 24 h later.